Quick Answer
Visco-3 denials most commonly result from insurer unfamiliarity with this specific product name. Visco-3 is a newer-to-market sodium hyaluronate product that shares its active ingredient with established brands. Many denials can be resolved by clarifying the product’s FDA approval and ensuring correct billing codes are used.
Why Visco-3 Injections Get Denied
Visco-3 (sodium hyaluronate) is manufactured by OrthogenRx (the same company behind GenVisc 850). It is designed as a 3-injection series, offering a streamlined treatment protocol compared to 5-injection alternatives.
1. Medical Necessity Not Established
The standard medical necessity denial applies to all HA products. Your insurer found that your documentation did not adequately demonstrate the need for viscosupplementation. This typically means insufficient imaging evidence, incomplete description of functional limitations, or unclear OA severity documentation.
2. Conservative Treatment Failure Not Documented
Plans require at least 3 months of documented conservative treatment. Records must include specific dates, treatments attempted, and outcomes for each approach.
3. Insurer Does Not Recognize Visco-3
Because Visco-3 has a smaller market presence than legacy brands, some insurer systems may not have it properly coded. This can result in denials labeled “not a covered product,” “unclassified drug,” or “experimental.” These denials are incorrect and can be overturned by demonstrating FDA approval.
4. Billing Code Issues
Visco-3’s HCPCS coding may vary. Some claims are billed under J7321 (sodium hyaluronate, shared with Hyalgan and Supartz) while others may use a miscellaneous code if the insurer’s system does not recognize the product. Incorrect or miscellaneous codes trigger higher denial rates.
5. Prior Authorization Not Obtained
Standard PA requirements apply. Always get PA before the first injection.
Billing Code Verification
Before treatment, have your provider’s billing office confirm which HCPCS code they will use for Visco-3 and verify that your insurer recognizes that code. Billing under a miscellaneous J-code significantly increases the chance of denial and complicates appeals.
Step-by-Step Appeal Process
Step 1: Review Your Denial Letter
Check the denial reason carefully. If it says “not covered,” “experimental,” or “not recognized,” this is a product recognition issue. If it cites medical necessity or documentation, the appeal focuses on clinical records.
Step 2: Gather Supporting Documentation
- Imaging: Knee X-rays documenting osteoarthritis
- Conservative treatment records: Dated records with specific treatments and outcomes
- Functional assessment: Documentation of daily limitations
- Product information: If the denial is a product recognition issue, include Visco-3’s FDA approval documentation and package insert
- Physician letter: Detailed letter of medical necessity
Step 3: Write Your Appeal Letter
For product recognition denials, clearly state that Visco-3 is FDA-approved and provide supporting documentation. For medical necessity denials, focus on comprehensive clinical records. See the template below.
Step 4: Submit and Follow Up
Submit via the plan’s preferred channel. For product recognition issues, a phone call to the plan’s medical or pharmacy policy team may resolve the issue quickly. Follow up within 5 business days.
Step 5: External Review Options
If internal appeal fails:
- Commercial plans: Independent external review
- Medicare Advantage: IRE, then ALJ
- Original Medicare: Redetermination, then QIC reconsideration
Sample Appeal Letter Template
[Your Name] [Your Address] [City, State, ZIP] [Date]
[Insurance Company Name] [Appeals Department Address] [City, State, ZIP]
RE: Appeal of Denial — Visco-3 (sodium hyaluronate) Injection Series Member ID: [Your Member ID] Claim Number: [Claim Number from Denial Letter] Date of Service: [Dates of Injections] Patient: [Your Name, DOB]
Dear Appeals Committee:
I am writing to appeal the denial of coverage for my Visco-3 injection series for [left/right] knee osteoarthritis, denied on [denial date] for the stated reason: “[exact denial reason].”
[If product recognition issue:] Product Clarification: Visco-3 is an FDA-approved sodium hyaluronate product manufactured by OrthogenRx for intra-articular treatment of knee osteoarthritis. It is in the same drug class as Hyalgan and Supartz and contains the same active ingredient. Visco-3 is not experimental or investigational. [Attach FDA approval documentation.]
Diagnosis: Osteoarthritis of the [left/right] knee (ICD-10: [M17.11 or M17.12]), confirmed by X-rays on [date] showing [findings].
Conservative Treatment History:
- Physical therapy: [number] sessions from [start date] to [end date]. Result: [limited improvement].
- NSAIDs: [medication] [dosage] from [start date] to [end date]. Result: [inadequate relief].
- Cortisone injection: [date]. Provided [X weeks] of temporary relief.
- Activity modification: [describe changes].
Functional Impact: My knee pain significantly limits [specific activities].
I respectfully request reversal of this denial. Supporting documentation is enclosed.
Sincerely, [Your Signature] [Your Printed Name] [Phone Number]
Enclosures: Denial letter, medical records, imaging, physician letter, FDA product documentation (if applicable), conservative treatment records
CPT and HCPCS Codes for Visco-3
| Code Type | Code | Description |
|---|---|---|
| HCPCS (Product) | J7321 | Hyaluronan or derivative, Hyalgan/Supartz, for intra-articular injection, per dose |
| CPT (Injection) | 20610 | Arthrocentesis, aspiration and/or injection of major joint (without ultrasound) |
| CPT (Injection w/ imaging) | 20611 | Arthrocentesis with ultrasound guidance |
| ICD-10 (Diagnosis) | M17.0 | Bilateral primary osteoarthritis of knee |
| ICD-10 (Diagnosis) | M17.11 | Primary osteoarthritis, right knee |
| ICD-10 (Diagnosis) | M17.12 | Primary osteoarthritis, left knee |
| Office Visit | 99213/99214 | Established patient office visit (if billed same day) |
Coding Note for Visco-3
Visco-3 is typically billed under J7321, shared with Hyalgan and Supartz. Each of the 3 injections is billed separately. Include the product-specific NDC number on each claim. If your provider’s billing system requires a different code, verify with your insurer before treatment.
Visco-3-Specific Coverage Facts
About Visco-3
- Manufacturer: OrthogenRx
- Active ingredient: Sodium hyaluronate
- Molecular weight: Low-medium (comparable to Hyalgan)
- Injection schedule: 3 weekly injections (2.5 mL each)
- FDA approved: Yes, for knee osteoarthritis
- Source: Avian-derived (rooster comb)
- Key feature: Streamlined 3-injection protocol; competitively priced
Medicare Coverage
Original Medicare covers Visco-3 under Part B for knee OA when billed under J7321. Patient pays 20% coinsurance after the $257 deductible (2026). PA generally not required under Original Medicare.
Commercial Insurance Coverage
- Some plans may not list Visco-3 by name but cover J7321 products
- Product recognition issues are more common than with legacy brands
- Prior authorization usually required
- Competitive pricing can work in your favor during appeals
- If your plan covers Hyalgan, it should cover Visco-3 under the same J-code
Common LCD Requirements
- Radiographic evidence of knee OA
- Failure of conservative therapy for 3+ months
- 6-month minimum between series
- Coverage for knee joint
- LCDs reference J-codes, so J7321 coverage includes Visco-3
Tips to Prevent Future Denials
- Confirm J7321 coverage with your plan before treatment
- Include the NDC number on all claims to identify the specific product
- Get prior authorization before starting the 3-injection series
- Complete all 3 injections on the weekly schedule
- Thoroughly document conservative treatment with dates and outcomes
- If your plan does not recognize Visco-3, have your provider contact the plan with FDA approval documentation before scheduling
- Use correct ICD-10 codes: M17.11 (right knee), M17.12 (left knee), M17.0 (bilateral)
Frequently Asked Questions
How long does a Visco-3 appeal take?
Product recognition issues may resolve in days with a phone call. Standard appeals take about 30 days. External review adds 30-60 days. Total: 1 day to 12 weeks.
What is the success rate for Visco-3 appeals?
Product recognition denials have a very high overturn rate once FDA status is demonstrated. Medical necessity denials follow the standard 40-60% overturn rate with complete documentation.
Can my doctor help with the appeal?
Yes. Your doctor can provide a letter of medical necessity and, for product recognition issues, supply FDA product information to the plan.
What if my second appeal is denied?
Request external review. If the insurer truly does not cover Visco-3, ask your provider about switching to Hyalgan (same active ingredient, same J-code) which may be on the plan’s formulary.
How is Visco-3 different from other 3-injection HA products?
Visco-3 contains sodium hyaluronate, the same active ingredient as Hyalgan. It is manufactured by OrthogenRx at a competitive price point. The 3-injection protocol is more convenient than 5-injection alternatives while still providing full-course treatment. Clinical effectiveness is comparable to other sodium hyaluronate products.